LGND – ligand pharmaceuticals incorporated (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

LGND

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

12/16

09:41 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

12/16

09:41 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

12/11

10:43 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

12/11

10:43 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

12/11

08:21 am

lgnd

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright.

Low Report

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright.

Report

11/12

09:25 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

11/12

09:25 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

11/8

02:42 pm

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

11/8

02:42 pm

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

11/8

01:09 pm

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

11/8

01:09 pm

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

11/8

11:15 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

11/8

11:15 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

11/8

08:46 am

lgnd

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $157.00 price target on the stock.

Low Report

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $157.00 price target on the stock.

Report

10/31

10:42 am

lgnd

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $157.00 price target on the stock.

Low Report

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $157.00 price target on the stock.

Report

10/28

10:03 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

10/28

10:03 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

10/3

08:17 am

lgnd

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $135.00 price target on the stock.

Low Report

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $135.00 price target on the stock.

Report

10/3

08:03 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

10/3

08:03 am

lgnd

Rating for LGND

Low Report

Rating for LGND

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.